- Home
- XERS vs VSECU Comparison
XERS vs VSECU Comparison
Compare XERS & VSECU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XERS | VSECU |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | XERS | VSECU |
|---|---|---|
| Price | $8.85 | $59.02 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $10.83 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 4.6K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | N/A | ★ 1.94 |
| Revenue | $49,590,000.00 | ★ $760,113,000.00 |
| Revenue This Year | $34.37 | N/A |
| Revenue Next Year | $22.86 | N/A |
| P/E Ratio | ★ N/A | $31.31 |
| Revenue Growth | ★ 142.67 | 9.88 |
| 52 Week Low | $5.25 | $38.45 |
| 52 Week High | $10.08 | $68.10 |
Technical Indicators
Market Signals| Indicator | XERS | VSECU |
|---|---|---|
| Relative Strength Index (RSI) | 59.95 | 58.74 |
| Support Level | $6.98 | $45.57 |
| Resistance Level | $9.01 | $65.35 |
| Average True Range (ATR) | 0.35 | 1.60 |
| MACD | 0.03 | 0.65 |
| Stochastic Oscillator | 94.66 | 83.64 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About VSECU VSE Corporation Tangible Equity Units
VSE Corp is a diversified aftermarket products and services company serving commercial and government markets. The Company's operations include aircraft and airframe parts supply and distribution, and MRO services of aircraft components and engine accessories. The Company operates as a single reportable segment: Aviation, which is a provider of aftermarket parts distribution and MRO services for components and engine accessories supporting commercial, business, and general aviation operators.